A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study

BACKGROUND: The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic and anti-diabetic properties and is effectively elevated in bloodstream by...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibuse, Toshiyuki, Maeda, Norikazu, Kishida, Ken, Kimura, Takekazu, Minami, Tomoko, Takeshita, Eriko, Hirata, Ayumu, Nakagawa, Yasuhiko, Kashine, Susumu, Oka, Akemi, Hayashi, Masumi, Nishizawa, Hitoshi, Funahashi, Tohru, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049487/
https://www.ncbi.nlm.nih.gov/pubmed/24884787
http://dx.doi.org/10.1186/1475-2840-13-96

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049487/
https://www.ncbi.nlm.nih.gov/pubmed/24884787
http://dx.doi.org/10.1186/1475-2840-13-96

Ejemplares similares